Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
HLA-DRα Double Nickase Plasmid (h): sc-401010-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- HLA-DRα Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- HLA-DRα Double Nickase Plasmid (h) and HLA-DRα Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting HLA-DRA. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: HLA-DRα Antibody (G-7): sc-55593
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HLA-DRα Double Nickase Plasmid (h) | sc-401010-NIC | 20 µg | $410.00 | |||
HLA-DRα Double Nickase Plasmid (h2) | sc-401010-NIC-2 | 20 µg | $410.00 |
HLA-DRA encodes the HLA-DRα chain, a core component of MHC class II HLA-DR heterodimers that present extracellularly derived peptides to CD4+ T cells. This antigen presentation pathway operates through endosomal processing, invariant chain (CD74) trafficking, and peptide loading regulated by HLA-DM, linking innate sensing to adaptive immune activation. HLA-DRα expression is tightly controlled by CIITA and interferon-γ–responsive transcriptional programs and is commonly used as a marker of antigen-presenting cell differentiation and activation. Altered HLA-DR biology has been implicated in immune-mediated disease susceptibility and inflammatory states through effects on peptide repertoire and T cell priming.
HLA-DRα Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the HLA-DRA locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within HLA-DRA. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt HLA-DRA function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of HLA-DRA-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.